New · CUSIP 15117B202 · who reports it, how much, and how much it matters to them
31 of the 720 hedge fund managers we track reported shares of Celldex Therapeutics, Inc. (Nasdaq: CLDX) on Form 13F for 30 June 2026. Between them they reported USD 704m. The largest position belongs to Kynam Capital Management, at USD 198m.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Kynam Capital Management1 fund on PPLI.com | USD 198m | 10.9% |
| 2 | Deep Track Capital1 fund on PPLI.com | USD 109m | 1.6% |
| 3 | Logos Global Management1 fund on PPLI.com | USD 78m | 3.4% |
| 4 | Eversept Partners3 funds on PPLI.com | USD 66m | 3.4% |
| 5 | Baker Bros. Advisors2 funds on PPLI.com | USD 44m | 0.2% |
| 6 | Millennium Management6 funds on PPLI.com | USD 44m | 0.0% |
| 7 | Rock Springs Capital Management2 funds on PPLI.com | USD 26m | 1.3% |
| 8 | Two Sigma Investments35 funds on PPLI.com | USD 25m | 0.0% |
| 9 | Braidwell12 funds on PPLI.com | USD 16m | 0.6% |
| 10 | Redmile Group10 funds on PPLI.com | USD 16m | 1.1% |
| 11 | Palo Alto Investors6 funds on PPLI.com | USD 15m | 2.1% |
| 12 | PFM Health Sciences3 funds on PPLI.com | USD 13m | 1.1% |
| 13 | Superstring Capital Management1 fund on PPLI.com | USD 11m | 6.8% |
| 14 | Sphera Funds Management1 fund on PPLI.com | USD 9m | 1.2% |
| 15 | Cinctive Capital Management5 funds on PPLI.com | USD 5.4m | 0.2% |
| 16 | Boothbay Fund Management2 funds on PPLI.com | USD 5.2m | 0.1% |
| 17 | Suvretta Capital Management4 funds on PPLI.com | USD 4.5m | 0.1% |
| 18 | POINT72 Asset Management17 funds on PPLI.com | USD 4.4m | 0.0% |
| 19 | HighVista Strategies27 funds on PPLI.com | USD 3.2m | 0.7% |
| 20 | Dafna Capital Management6 funds on PPLI.com | USD 2.5m | 0.5% |
| 21 | Burkehill Global Management5 funds on PPLI.com | USD 1.9m | 0.1% |
| 22 | Aquatic Capital Management3 funds on PPLI.com | USD 1.6m | 0.1% |
| 23 | Engineers Gate Manager1 fund on PPLI.com | USD 1.3m | 0.0% |
| 24 | Capital Fund Management S.A.12 funds on PPLI.com | USD 1.1m | 0.0% |
| 25 | Balyasny Asset Management25 funds on PPLI.com | USD 979,000 | 0.0% |
| 26 | Verdad Advisers6 funds on PPLI.com | USD 770,000 | 0.7% |
| 27 | D. E. Shaw & Co.15 funds on PPLI.com | USD 663,000 | 0.0% |
| 28 | Capstone Investment Advisors25 funds on PPLI.com | USD 440,000 | 0.0% |
| 29 | Brevan Howard Capital Management39 funds on PPLI.com | USD 303,000 | 0.0% |
| 30 | Magnetar Financial93 funds on PPLI.com | USD 296,000 | 0.0% |
| 31 | The Quarry1 fund on PPLI.com | USD 3,163 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Kynam Capital Management | USD 198m | 10.9% |
| 2 | Superstring Capital Management | USD 11m | 6.8% |
| 3 | Eversept Partners | USD 66m | 3.4% |
| 4 | Logos Global Management | USD 78m | 3.4% |
| 5 | Palo Alto Investors | USD 15m | 2.1% |
| 6 | Deep Track Capital | USD 109m | 1.6% |
| 7 | Rock Springs Capital Management | USD 26m | 1.3% |
| 8 | Sphera Funds Management | USD 9m | 1.2% |
| 9 | PFM Health Sciences | USD 13m | 1.1% |
| 10 | Redmile Group | USD 16m | 1.1% |
Celldex Therapeutics, Inc. trades under the symbol CLDX on the Nasdaq. Its CUSIP, the code used on Form 13F, is 15117B202.
31 of the 720 hedge fund managers PPLI.com tracks reported Celldex Therapeutics, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Kynam Capital Management (USD 198m), Deep Track Capital (USD 109m), Logos Global Management (USD 78m), Eversept Partners (USD 66m) and Baker Bros. Advisors (USD 44m).
31 managers in our coverage reported it, and between them they run 370 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Kynam Capital Management, where the position was 10.9% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Celldex Therapeutics, Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.